FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280541682> ?p ?o ?g. }

• W4280541682 abstract "Crohn's disease (CD) is an inflammatory bowel disease that causes inflammation and stricture, of any part of the mucosa and the gut wall. It forms skip lesions, sparing the areas in between the affected parts of the gastrointestinal tract. Crohn's disease could have one of three complications; fistula, intestinal obstruction due to stricture, or gastrointestinal inflammation presenting as severe diarrhoea. Stem cell therapy (SCT) is an innovative treatment that has been recently used in CD. The exact role of SCT in CD is still unclear. Stem cells modify the immunity of the patients or act as a reset tool for the immune system as in the case of systemically-injected stem cells, or regenerate the affected area of necrotic and inflammatory tissue as in the case of local injection into the lesion. Stem cells are a wide variety of cells including pluripotent stem cells or differentiated stem cells. The hazards range from rejection to symptomatic manifestations as fever or increase infection. OBJECTIVES: The objective of this Cochrane systematic review is to assess the effects of stem cell transplantation compared to standard of care alone or with placebo on efficacy and safety outcomes in patients with refractory CD.We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trial registries (Clinicaltrials.gov, World Health Organization-International Clinical Trials Registry Platform WHO ICTRP) from inception to 19 March 2021, without any language, publication year, or publication status restrictions. In addition, we searched references of included studies and review articles for further references. An update of the published studies was done during the writing of the review.We included only randomised controlled trials (RCTs) that assessed the effectiveness and safety of SCT in refractory CD versus standard care alone (control) or with placebo.Two review authors (SEN and SFA) independently screened the studies retrieved from the search results for inclusion, extracted data and assessed the risk of bias. Any disagreement was resolved through a consensus between the authors. We used standard methodological procedures expected by Cochrane.We conducted our search on 19 March 2021 and identified 639 records. We added two records by a manual search of the published reviews on the topic to a total of 641 records. The Covidence program removed 125 duplicates making a total of 516 reports. Two review authors (SEN and SFA) screened titles and abstracts and excluded 451 records with the remaining 65 for full-text records screened independently by the two authors; only 18 studies were considered for inclusion. We included seven RCTs with a total of 442 participants for the meta-analysis. The intervention group included 234 patients, and the control group included 208 patients. Nine trials are ongoing and, two abstracts are awaiting classification. All patients in the control and intervention groups received the standard therapy for CD. Only three studies used blinding methods for the control group in the form of a placebo, with one study of the three stated that the blinding method was inefficient. The patients and personnel were aware of the intervention in the rest of the four studies as they were open-label trials. However, the effect of unblinding was balanced by the low risk of detection bias in five of the included studies. The evidence is uncertain about the effect of SCT on achieving clinical remission as compared to control/placebo (risk ratio (RR) 1.88, 95% Confidence Interval (CI) 0.80 to 4.41; 3 studies; low-certainty evidence). The evidence is very uncertain about the effect of SCT on achieving Crohn's Disease Activity Index (CDAI) <150 at 24 weeks compared to control (RR1.02 95% CI 0.67 to 1.56; 4 studies; very-low certainty evidence). SCT is likely to achieve fistula closure as compared to the control/placebo both in the short term (RR 1.48, 95% CI 1.12 to 1.96); low-certainty evidence) and in the long term (RR 1.42, 95% CI 1.09 to 1.87; 4 studies; low-certainty evidence) follow-up. The evidence is very uncertain about the effect of SCT to cause no difference in the number of total adverse events as compared to the control/placebo (RR 0.99, 95% CI [0.88 to 1.13); 4 studies; very-low-certainty evidence). However, SCT is likely to increase the number of serious adverse events as compared to the control/placebo (RR 1.22, 95% CI 0.88 to 1.67; 7 studies; low-certainty evidence). The evidence is very uncertain about the effect of SCT to decrease the withdrawal due to adverse events as compared to the control/placebo (RR 0.78, 95% CI 0.32 to 1.89; 3 studies; very-low certainty evidence). Funding by pharmaceutical companies was found in three studies, with one including more than 50% of our studied population.SCT shows an uncertain effect on clinical remission with low certainty of evidence. SCT shows an uncertain effect on CDAI score to reach <150 after 24 weeks of treatment, with very low certainty evidence. SCT shows beneficial effects on fistula-closure during short and long-term follow-up with low-certainty evidence in both outcomes. There was no change in the total number of adverse events with SCT as compared to control, with very low certainty evidence. While there was a moderate effect on increasing the number of serious adverse events in the SCT group, as compared to the control with low-certainty evidence. Withdrawal due to adverse events was slightly higher in the control group with very low certainty evidence. All the participants were refractory to standard medical treatment, but the number of participants was small, this may limit the generalizability of the results. Further research is needed for validation. More objective outcomes are needed in the assessment of stem cell effectiveness in the treatment of Crohn's disease, especially the intestinal CD subtype; with standardization of the dose, methods of stem cell preparation, route of administration, and inclusion criteria to the studies to achieve clear results." @default.
• W4280541682 created "2022-05-22" @default.
• W4280541682 creator A5021174253 @default.
• W4280541682 creator A5049869677 @default.
• W4280541682 creator A5053957158 @default.
• W4280541682 creator A5073525151 @default.
• W4280541682 date "2022-05-13" @default.
• W4280541682 modified "2023-09-26" @default.
• W4280541682 title "Stem cell transplantation for induction of remission in medically refractory Crohn’s disease" @default.
• W4280541682 cites W1480595770 @default.
• W4280541682 cites W1562235336 @default.
• W4280541682 cites W1666594451 @default.
• W4280541682 cites W1774343840 @default.
• W4280541682 cites W1825587443 @default.
• W4280541682 cites W1827907298 @default.
• W4280541682 cites W1852715977 @default.
• W4280541682 cites W1872007329 @default.
• W4280541682 cites W1910349427 @default.
• W4280541682 cites W1967091196 @default.
• W4280541682 cites W1969748400 @default.
• W4280541682 cites W1973294883 @default.
• W4280541682 cites W1997721952 @default.
• W4280541682 cites W2004608617 @default.
• W4280541682 cites W2014407461 @default.
• W4280541682 cites W2016203423 @default.
• W4280541682 cites W2022534116 @default.
• W4280541682 cites W2035334520 @default.
• W4280541682 cites W2041243709 @default.
• W4280541682 cites W2041288820 @default.
• W4280541682 cites W2044585426 @default.
• W4280541682 cites W2046445771 @default.
• W4280541682 cites W2052118031 @default.
• W4280541682 cites W2054104356 @default.
• W4280541682 cites W2055179655 @default.
• W4280541682 cites W2068195414 @default.
• W4280541682 cites W2068529268 @default.
• W4280541682 cites W2070369118 @default.
• W4280541682 cites W2072179061 @default.
• W4280541682 cites W2077531651 @default.
• W4280541682 cites W2082654469 @default.
• W4280541682 cites W2089944772 @default.
• W4280541682 cites W2094131843 @default.
• W4280541682 cites W2102013054 @default.
• W4280541682 cites W2103771634 @default.
• W4280541682 cites W2105734762 @default.
• W4280541682 cites W2110286478 @default.
• W4280541682 cites W2113933847 @default.
• W4280541682 cites W2133426555 @default.
• W4280541682 cites W2136279247 @default.
• W4280541682 cites W2137935439 @default.
• W4280541682 cites W2140605565 @default.
• W4280541682 cites W2156390096 @default.
• W4280541682 cites W2160666118 @default.
• W4280541682 cites W2170258627 @default.
• W4280541682 cites W2201119837 @default.
• W4280541682 cites W2202486845 @default.
• W4280541682 cites W2220139942 @default.
• W4280541682 cites W2285722270 @default.
• W4280541682 cites W2327615325 @default.
• W4280541682 cites W2344387435 @default.
• W4280541682 cites W2410351669 @default.
• W4280541682 cites W2472546488 @default.
• W4280541682 cites W2474206452 @default.
• W4280541682 cites W2478193138 @default.
• W4280541682 cites W2523706394 @default.
• W4280541682 cites W2604306934 @default.
• W4280541682 cites W2606558706 @default.
• W4280541682 cites W2611455365 @default.
• W4280541682 cites W2732172136 @default.
• W4280541682 cites W2744343135 @default.
• W4280541682 cites W2751308524 @default.
• W4280541682 cites W2755176823 @default.
• W4280541682 cites W2766046358 @default.
• W4280541682 cites W2780607073 @default.
• W4280541682 cites W2794595980 @default.
• W4280541682 cites W2796319877 @default.
• W4280541682 cites W2804455798 @default.
• W4280541682 cites W2806162339 @default.
• W4280541682 cites W2886198653 @default.
• W4280541682 cites W2896984918 @default.
• W4280541682 cites W2897151635 @default.
• W4280541682 cites W2898049276 @default.
• W4280541682 cites W2903080326 @default.
• W4280541682 cites W2910256679 @default.
• W4280541682 cites W2912374965 @default.
• W4280541682 cites W2913628889 @default.
• W4280541682 cites W2913914976 @default.
• W4280541682 cites W292732913 @default.
• W4280541682 cites W2941747438 @default.
• W4280541682 cites W2947831096 @default.
• W4280541682 cites W2950422746 @default.
• W4280541682 cites W2951537203 @default.
• W4280541682 cites W2958697083 @default.
• W4280541682 cites W2963679336 @default.
• W4280541682 cites W2969354116 @default.
• W4280541682 cites W2976362764 @default.
• W4280541682 cites W2984128211 @default.
• W4280541682 cites W2997172899 @default.
• W4280541682 cites W3011991430 @default.
• W4280541682 cites W3030360237 @default.

• next